116 related articles for article (PubMed ID: 8117608)
1. Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC).
Van Hoef ME; Radford JA; Jones A; Smith IE; Earl HM; Woll PJ; Thatcher N
Ann Oncol; 1993 Dec; 4(10):877-81. PubMed ID: 8117608
[TBL] [Abstract][Full Text] [Related]
2. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Wenger M; Lange W; Mertelsmann R
Ann Oncol; 1997 Jan; 8(1):49-56. PubMed ID: 9093707
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
5. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
[TBL] [Abstract][Full Text] [Related]
6. Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer.
Iwasaki Y; Nagata K; Nakanishi M; Natuhara A; Kubota Y; Ueda M; Arimoto T; Hara H
Chest; 2005 Oct; 128(4):2268-73. PubMed ID: 16236883
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
Luikart SD; Herndon JE; Hollis DR; MacDonald M; Maurer LH; Crawford J; Clamon GH; Wright J; Perry MC; Ozer H; Green MR
Am J Clin Oncol; 1997 Feb; 20(1):24-30. PubMed ID: 9020283
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
9. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
Bessho A; Ueoka H; Kiura K; Tabata M; Sunami K; Katayama Y; Yamane H; Hiraki A; Harada M
Anticancer Res; 1999; 19(1B):693-8. PubMed ID: 10216478
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen.
Murren JR; Gollerkeri A; Anderson S; Lutzker S; Del Prete S; Zelterman D; Garrison L; Smith B
Yale J Biol Med; 1998; 71(5):355-65. PubMed ID: 10527363
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of ifosfamide, carboplatin, etoposide and GM-CSF in small cell lung cancer.
Thongprasert S
J Med Assoc Thai; 2000 May; 83(5):549-53. PubMed ID: 10863902
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
13. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
Katakami N; Takada M; Negoro S; Ota K; Fujita J; Furuse K; Ariyoshi Y; Ikegami H; Fukuoka M
Cancer; 1996 Jan; 77(1):63-70. PubMed ID: 8630941
[TBL] [Abstract][Full Text] [Related]
15. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
16. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.
Walewski J; Romejko-Jarosińska J; Zwoliński J; Falkowski S; Siedlecki P
Med Oncol; 1996 Dec; 13(4):199-205. PubMed ID: 9152970
[TBL] [Abstract][Full Text] [Related]
18. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
[TBL] [Abstract][Full Text] [Related]
19. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.
Skarlos DV; Samantas E; Kosmidis P; Fountzilas G; Angelidou M; Palamidas P; Mylonakis N; Provata A; Papadakis E; Klouvas G
Ann Oncol; 1994 Sep; 5(7):601-7. PubMed ID: 7993835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
